Navigation Links
Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009.

ADA: Ernest N. Morial Convention Center, New Orleans, LA.

    Saturday, June 6:  Embargo Lifts June 6 at 9:00 a.m. CT
    Oral Presentation
    Abstract: 37-OR
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, PA
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss:
    A 56-week Phase 3 Study"
    Time: 9:00 a.m. CT
    Location: Room 255

    Monday, June 8:  Embargo Lifts June 6 at 10:00 a.m. CT
    Poster Presentation*
    Abstract: 1731-P
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, Pa.
    Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves
    Quality of Life"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    Poster Presentation*
    Abstract: 1730-P
    Presenter: Samuel Klein, M.D., Washington University School of Medicine,
    St. Louis, Mo.
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss
    Without Worsening Psychiatric Symptoms"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    * Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT
    at a Poster Reception in Hall E

ENDO: Walter E. Washington Convention Center, Washington, D.C.

    Friday, June 12:  Embargo Lifts June 12 at 11:15 a.m. ET
    Oral Presentation
    Abstract: OR18-5
    Presenter: F. Xavier Pi-Sunyer, M.D., M.P.H., The New York Obesity
    Research Center, St. Luke's Roosevelt Hospital Center, New York, N.Y.
    Title: "Combination Therapy with Naltrexone + Bupropion Causes Significant
    Weight Loss and Improves Cardiometabolic Parameters in Obese Individuals:
    A Randomized Phase 3 Study Over 56 Weeks"
    Time: 11:15 a.m. ET
    Location: Room 152AB

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
Breaking Biology News(10 mins):